Drug intelligence / Profile preview

nora520

Development stage: Phase 2
Lead developer: Gerbera Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

NORA520 is an oral prodrug that is hydrolyzed to brexanolone. It functions as a positive allosteric modulator (PAM) of the GABA-A receptor. The drug consists of an active moiety with rapid onset of action plus two additional moieties that prolong half-life and promote oral absorption. NORA520 is being developed primarily for the treatment of severe postpartum depression (PPD), with a dosing regimen of 5 doses over 3 days.

Other names: Brexanolone Prodrug

Targets

GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on nora520.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nora520.

Explore the full profile